A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus
NCT03985293 on ClinicalTrials.gov · last registry update 2022-06-30
An unusually large phase 2: 412 participants, more than double the 110 typical for the stage. The sponsor logged completion for 8 June 2021. Primary outcome, as filed: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 16. danuglipron is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- COMPLETED
- Phase
- P2
- Drug
- danuglipron
- Sponsor
- Pfizer
- Sponsor type
- Industry
- Enrollment
- 412
- Started
- 2019-10-15
- Primary completion
- 2021-06-08 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 16
Conditions studied
Diabetes Mellitus, Type 2
Every field above is taken directly from the registry record. See all detected changes across the class, or the danuglipron page for this molecule’s full trial and approval history.